Marco Ruella MD
Hematologic Oncology
Assistant Professor of Medicine and Scientific Director, Lymphoma Program
Join to View Full Profile
3400 Civic Center BlvdPerelman Center for Advanced Medicine, SPE 8-112Philadelphia, PA 19104
Phone+1 215-746-4880
Dr. Ruella is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Penn MedicinePost-Doctoral Fellowship, 2012 - 2018
University of TorinoSpecialty in Hematology, Clinical Hematology and Cell Therapy, cum Laude, 2008 - 2012
University of Torino Faculty of MedicineClass of 2007
Certifications & Licensure
PA State Medical License 2018 - 2026
Publications & Presentations
PubMed
- Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.Jakub Svoboda, Daniel J Landsburg, James Gerson, Sunita D Nasta, Stefan K Barta
The New England Journal of Medicine. 2025-05-08 - Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges.Fabio Luciani, Arman Safavi, Puneeth Guruprasad, Linhui Chen, Marco Ruella
Blood Cancer Discovery. 2025-05-05 - CD22-targeted chimeric antigen receptor-modified T cells for children and adults with relapse of B-cell acute lymphoblastic leukemia after CD19-directed immunotherapy.Regina M Myers, Amanda M DiNofia, Yimei Li, Caroline Diorio, Hongyan Liu
Journal for Immunotherapy of Cancer. 2025-04-17
Journal Articles
- Induction of Resistance to Chimeric Antigen Receptor T Cell Therapy by Transduction of a Single Leukemic B CellVijay G Bhoj, David M Barrett, Carl H June, Stephan A Grupp, David E Ambrose, Saar I Gill, Marco Ruella, Bruce L Levine, Shannon L Maude, Nature
- Genome-Editing Technologies in Adoptive T Cell Immunotherapy for CancerNathan Singh, Marco Ruella, Carl H June, Current Hematologic Malignancy Reports
Abstracts/Posters
- Hospitalization Patterns with Commercial CAR T-Cell Therapy: A Single Institution ExperienceMarco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell LymphomasMarco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell EfficacyMarco Ruella, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Authored Content
- The Quest To Cure CLL: “Remarkable” Results With New StrategySeptember 2023
- Interleukin-18 Secreting Autologous Anti-CD19 CAR T-cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-cell TherapyDecember 2022
Press Mentions
Simple Dietary Supplement Could Supercharge Cancer-Fighting Immune CellsDecember 29th, 2024- Keto Diet Metabolite May Power up CAR T Cells to Kill CancerDecember 9th, 2024
- Keto Diet Might Increase Effectiveness of Certain Cancer TreatmentDecember 9th, 2024
- Join now to see all
Grant Support
- MODULATION OF CD5 SIGNALING TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCERUNIVERSITY OF PENNSYLVANIA2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
